BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The applicant Genzyme B.V. submitted on 5 July 2000 an application for Marketing Authorisation to 
the European Agency for the Evaluation of Medicinal Products (EMEA) for Fabrazyme, in accordance 
with the centralised procedure falling within the scope of Part A of the Annex to Council Regulation 
No (EEC) 2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur: 
Dr. H. van Bronswijk 
Co-Rapporteur:  Dr. P. Kurki 
Scientific Advice: 
The applicant did not seek Scientific Advice at the CPMP.  
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The procedure started on 18 July 2000. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on  
28 September 2000 . The Co-Rapporteur's first Assessment Report was circulated to all CPMP 
members on 26 September 2000. 
During  the  meeting  on  14-16  November  2000  the  CPMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 16 November 2000. 
The  company  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on  
11 December 2000. 
The Rapporteur circulated the joint response Assessment Report on the applicant’s responses to 
the List of Questions to all CPMP members on  23 January 2001. 
During the meeting on 27 February – 1 March 2001, the CPMP agreed on a list of outstanding 
issues to be addressed by the applicant in writing and if necessary during an oral explanation. 
The list of outstanding issues was sent to the applicant on 28 February 2001.  
The applicant provided written information on these outstanding issues to all CPMP members 
on  13  March  2001.  The  joint  Rapporteur/Co-rapporteur  assessment  report  on  the  written 
responses  to  the  list  of  outstanding  issues  was  circulated  to  all  CPMP  members  on  21  March 
2001. 
During  the  CPMP  meeting  on  27-29  March  2001,  post-authorisation  commitments  were 
clarified by the applicant before the CPMP. 
During the meeting on  27 – 29 March 2001 the CPMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to Fabrazyme on 29 March 2001. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 3 August 2001. 
1/1 
EMEA 2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
